Stocks Abbott Laboratories


  • Questar and Alere are big market movers Monday, 1 Feb 2016 | 4:25 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq stock market:. Questar Corp., up $4.60 to $24.99. Aetna Inc., up $1.53 to $103.37.

  • Drugmaker Abbott to buy Alere for $5.8B Monday, 1 Feb 2016 | 10:19 AM ET
    Employees walk near an Abbott Laboratories sign at the company's headquarters complex in Abbott Park, Illinois.

    Drugmaker Abbott Laboratories said it would acquire Alere for $5.8 billion to boost its global diagnostics presence.

  • Abbott to buy medical test provider Alere Monday, 1 Feb 2016 | 8:50 AM ET

    NEW YORK— Abbott Laboratories will buy Alere for $4.8 billion as it tries to expand its medical-testing business. The deal is worth $5.8 billion when restricted stock, stock options and preferred shares are included, the company said Monday. Alere Inc., based in Waltham, Massachusetts, makes tests used to diagnosis the flu, HIV, malaria and several other diseases...

  • NEW YORK— Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq stock market:. Under Armour Inc., up $15.49 to $84.07. PayPal Holdings Inc., up $2.65 to $34.24.

  • US stocks rise as oil prices jump again; tech climbs Thursday, 28 Jan 2016 | 10:36 AM ET

    NEW YORK— U.S. stocks rose Thursday as the price of oil climbed for the third day in a row on hopes that major oil exporters would cut production. Sports apparel maker Under Armour also surged. Energy prices and companies rose after the Kremlin said it is discussing the state of the oil markets with Saudi Arabia and OPEC.

  • Abbott's stock tumbles as outlook weighed by Venezuela Thursday, 28 Jan 2016 | 7:53 AM ET

    ABBOTT PARK, Ill.— Abbott Laboratories' stock tumbled Thursday after the maker of infant formula, medical devices and drugs gave a disappointing earnings forecast, citing weakness in its Venezuelan business. The Abbott Park, Illinois- based company earned $767 million, or 51 cents per share, for its fourth quarter. Analysts surveyed by Zacks Investment Research...

  • It was for a powerful antibiotic cocktail marketed in India by a unit of U.S. pharmaceutical giant Abbott Laboratories. And a government-appointed panel in India recommended to the Health Ministry last year that it not be approved for sale here, citing lack of safety and efficacy data and a high potential for "misuse." In fact, the drug has not been approved by the...

  • Shares of medtech companies such as Edwards Lifesciences, Boston Scientific and Becton Dickinson have outperformed the broad healthcare sector, and especially pharmaceutical and biotech shares, over the past two months since U.S. presidential candidate Hillary Clinton tweeted she planned to address specialty drug "price gouging." He said he likes...

  • Medtronic Plc, Abbott Laboratories, Edwards Lifesciences Corp and HeartWare International Inc in recent months have spent a total of $2 billion to buy young companies developing versions of the technology. Nearly 6 million people in the United States may suffer from mitral disease, and Wall Street analysts say it could be the next multibillion-dollar...

  • SANTIAGO, Nov 26- Chile's financial regulator said on Thursday it had fined Santiago- based businessman Juan Bilbao Hormaeche some $3.2 million for using insider information to trade shares of drug company CFR Pharmaceuticals SA. The move came about a month after the U.S. Securities and Exchange Commission reached a $13.2 million dollar settlement with...

  • The runaway inversion craze, in three charts Tuesday, 24 Nov 2015 | 11:30 AM ET

    Pfizer's proposed acquisition of Allergan will be one of the biggest tax inversions yet.

  • ORLANDO, Fla., Nov 9- Patients with severe leakage from the mitral valve of the heart who had the valve replaced had significantly lower rates of recurrence and heart failure two years after the procedure than those who underwent surgical repair, according to data presented on Monday. There was also a higher rate of reported heart failure events, 48 versus 29, and...

  • China's problems are bigger than babies Monday, 2 Nov 2015 | 1:53 PM ET
    Twin boys Sun Qiyu and Sun Qichun hold China's national flags on the Tiananmen Gate in Beijing November 2, 2015. China must continue to enforce its one-child policy until new rules allowing all couples to have two children go into effect, the top family planning body said.

    China's easing of the one-baby rule may not be enough to cure its slowing fertility rate and aging population problem.

  • Oct 30- AbbVie Inc reported higher quarterly sales and net income on Friday and forecast double-digit growth of earnings per share through 2020, putting the drugmaker in line to beat Wall Street's current expectations. AbbVie, which was spun out of Abbott Laboratories in 2013, expects revenue of $37 billion in 2020, which is $5 billion more than the current...

  • NEW YORK, Oct 23- A former board member of Chile's CFR Pharmaceuticals SA has reached a $13.2 million settlement to resolve charges by a U.S. regulator that he engaged in insider trading ahead of Abbott Laboratories' $2.9 billion acquisition of the drug company. The SEC also agreed to drop charges against a business associate of Bilbao, Tomas Andres Hurtado...

  • Is guidance pointing to another soft quarter ahead? Tuesday, 20 Oct 2015 | 6:53 PM ET
    Traders on the Floor

    A hot sports car stock could leave a group of blue chips in its dust, as traders watch earnings reports to see if corporate profits are cooling.

  • Market eyes earnings as Fed leaves it in confusion Friday, 16 Oct 2015 | 6:33 PM ET
    NYSE Traders

    So far the earnings season has been lackluster, and some high-profile warnings have already given investors pause.

  • *Abuse, smuggling of codeine cough syrups worries India. *India pressuring pharma firms to check supplies. India's Cipla stopped making the product last year owing to regulatory demands, and U.S.-based Abbott Laboratories and Pfizer have had to reduce batch sizes by up to half, cutting how much medicine their factories can produce.

  • Oct 12- A novel dissolving heart stent developed by Abbott Laboratories proved comparably safe and effective as its market-leading Xience stent in a large, late-stage trial that will be used to seek U.S. approval of the device, according to data presented at a medical meeting on Monday. The bioabsorbable Absorb stent succeeded in demonstrating...